Yale Cancer Center Study Shows Immunotherapy Prior to Surgery May Help Destroy High-Risk Breast Cancer
A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.
Geneticist Sidi Chen Receives Large Award Which Will Further His Breast Cancer Work
This Department of Defense award goes to the “best and brightest in their fields,” and recognizes “creative and innovative individuals.” Investigators are chosen for their ability “to go beyond conventional thinking” in their respective areas of expertise.
Sentinel Lymph Node Biopsy Provides no Benefit for Stage Zero Breast Cancer, Yale School of Public Health Study Finds
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS), gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.
HEALTH NOTES: Black and Hispanic Cancer Patients Are Underrepresented in Clinical Trials
A new study has shown that clinical trials for new cancer medications rarely analyze data on safety and effectiveness by race and that black and Hispanic patients are consistently underrepresented among participants.
Improving Breast Cancer Outcomes for African Women
For eight days in early June, Melissa Durand, MD, volunteered at the second-largest teaching hospital in Ghana, West Africa. Decades earlier, mammography technologist Judith Abaidoo of Yale New Haven Hospital’s Shoreline Medical Center became one of the first women to perform mammograms in Ghana, where the five-year breast cancer survival rate is estimated to be only 25%.
More women in U.S. receive 3-D mammography but disparities remain
Use of 3-D mammography, an advanced form of breast cancer screening, has risen rapidly in recent years, according to Yale Cancer Center researchers in a new study. But adoption of the technology varies widely, reflecting emerging disparities in care, they said.
Better Science, Better Lives: Women's Health Research at Yale is Working for You
Across the country, it’s becoming clearer every day: We must study the health of women. We must study the influence of sex-and-gender differences on health. And it’s time for all aspects of medical research and practice to embrace this change.
Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
New Study in JNCCN Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40
A new study from the Stanford Cancer Institute finds that young women who are treated with chemotherapy for breast cancer but have residual tumor in either the breast or lymph nodes have higher chances of recurrence compared to those with no evidence of any residual invasive tumor (pathologic complete response). “By assessing patient outcomes in a relatively large group of women under 40 treated with neoadjuvant chemotherapy, this study adds significantly to the existing literature,” said Meena S. Moran, MD, Professor and Director of Yale Radiation Therapy Breast Program, Yale Cancer Center/Smilow Cancer Hospital, Member, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Breast Cancer.